| Generic name | Pomalidomide |
| Pronunciation | Pom-a-LID-oh-mide |
| Brand name(s), other common name(s) | Pomalyst® |
| Drug type | Immunomodulatory agent with antineoplastic activity |
| How the drug is given | By mouth |
Indications and Usage
Pomalidomide is FDA approved to treat people with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate. Clinical benefit, such as improvement in survival or symptoms, has not been verified.
Side effects needing medical attention
Females who are pregnant or who plan to become pregnant must not take pomalidomide. Pomalidomide may cause serious side effects including possible birth defects (deformed babies) or death of an unborn baby. Also needing medical attention: shortness of breath; chest pain; arm or leg swelling; Low white blood cells (neutropenia); low platelets (thrombocytopenia); low red blood cells (anemia); tiredness and weakness; constipation; shortness of breath; diarrhea; fever; back pain; nausea; blood clots in your veins and lungs.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.